Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHD

Graft-versus-host Disease Clinical Trial

Official title:

Safety and Efficacy of Autologous Platelet Rich Plasma and Platelet Poor Plasma Eye Drops in the Treatment of Ocular Graft-Versus-Host Disease

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02561520
• Other study ID #: PRO15070211
• Status: Withdrawn
• Phase: Phase 1
• First received: September 17, 2015
• Last updated: August 24, 2017
• Start date: December 2016
• Est. completion date: September 2018

Study information

• Verified date: August 2017
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of autologous Platelet Rich Plasma (PRP) and Platelet Poor Plasma (PPP) eye drops four times a day in the treatment of ocular graft versus host disease (O-GVHD). In addition to their current medication (except autologous serum drops), patients will receive PRP and PPP drops.

Description:

Ocular involvement can be quite symptomatic in patients with chronic graft-versus-host disease (GVHD). The impact of ocular GVHD on quality of life (QOL) in patients with chronic GVHD has been studied in a prospective, multicenter, longitudinal, observational study and showed that ocular GVHD affects 57% of patients within 2 years of chronic GVHD diagnosis. Strong evidence suggested that ocular GVHD is associated with worse overall health-related QOL. Significant worsening of vision-related QOL in ocular GVHD has been reported. Ocular GVHD is devastating and there is no effective treatment available so far. The importance of this study is that for the first time in the nation, our institute will evaluate the safety and efficacy of topical autologous blood product (PRP and PPP) to treat ocular surface disease associated with ocular GVHD.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18 years.

• Willing and able to provide written informed consent.

• Willing and able to comply with study assessments for the full duration of the study.

• Diagnosis of ocular GVHD.

• Minimum corneal fluorescein staining of 4 (NEI grading scheme, 0-15) in at least one eye.

• In good stable overall health.

Exclusion Criteria:

• Remission from primary cancer in more than 5 years.

• History of thrombocytopenia (platelet<50,000) in the last 2 weeks before study entry.

• Ocular or periocular malignancy.

• Significant change, as judged by the PI, in systemic immunosuppressive regimen before 2 weeks of study entry.

• Any change in dosage of tetracycline compounds (tetracycline, doxycycline, and minocycline) within the last month.

• Any change in frequency of preserved anti-glaucoma medications before 2 weeks of study entry.

• Current use of topical steroids more than twice a day.

• Change in frequency of topical cyclosporine and/or topical kineret within the last month.

• Signs of current infection, including fever and current treatment with antibiotics.

• Intra-ocular surgery or ocular laser surgery within the last 3 months.

• Has worn contact lenses, except for bandage contact lens or rigid gas permeable lens or scleral contact lens, for the last 2 weeks prior to the study or would be unable to stay off contact lenses for the study duration.

• Any condition (including language barrier) that precludes patient's ability to comply with study requirements including completion of study.

Related Conditions & MeSH terms

• Graft vs Host Disease
• Graft-versus-host Disease

Intervention

Biological:
• PRP eye drops
Eye drops 4x a day, patients will start this eye drop first.
• PPP eye drops
Eye drops 4x a day, patients will start this eye drops after PRP.

Locations

Country	Name	City	State
United States	UPMC Eye Center	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Ladan Espandar

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment-Related Adverse Events	Safety and tolerability of topical autologous PRP and PPP four times a day will be monitored by the occurrence of systemic and ocular adverse events in addition to symptoms directly related to the instillation or use of the autologous blood products. The severity of each adverse event and relation to the study medication will be graded possibly, probably, or definitely related. Tolerability measures will be graded from trace to severe using a direct query method at each visit.	8 Weeks
Secondary	Efficacy of topical autologous PRP and PPP as measured by the National Eye Institute (NEI) grading scale	To evaluate the efficacy of topical autologous PRP and PPP four times a day in reducing signs of dry eye in ocular GVHD, cornea fluorescein staining will be used using NEI grading system.	8 weeks
Secondary	Efficacy of topical autologous PRP and PPP as measured by Tear Film Break Up Time (TBUT)	To evaluate the efficacy of topical autologous PRP and PPP four times a day in reducing signs of dry eye in ocular GVHD,Tear Film Break Up Time (TBUT) will be used.	8 weeks
Secondary	Efficacy of topical autologous PRP and PPP as measured by Schirmer Test I	To evaluate the efficacy of topical autologous PRP and PPP four times a day in reducing signs of dry eye in ocular GVHD, Schirmer test without topical anesthetic will be used.	8 weeks
Secondary	Efficacy of topical autologous PRP and PPP as measured by expression of cellular markers of inflammation using real-time polymerase chain reaction (RT-PCR)	To evaluate the efficacy of topical autologous PRP and PPP four times a day in reducing signs of dry eye in ocular GVHD, expression of cellular markers of inflammation such as (intercellular adhesion molecule-1 (ICAM-1), interleukin IL-1b, IL-2, IL-6, IL-8, IL-10, IL-17, IL-23, interferon IFN-g and tumor necrosis factor TNF-a) will be used using real-time polymerase chain reaction (RT-PCR) on schirmer filter papers.	8 weeks
Secondary	Efficacy of topical autologous PRP and PPP as measured by expression of cellular markers of inflammation using flow cytometry (FC)	To evaluate the efficacy of topical autologous PRP and PPP four times a day in reducing signs of dry eye in ocular GVHD, expression of cellular markers of inflammation such as (intercellular adhesion molecule-1 (ICAM-1), interleukin IL-1b, IL-2, IL-6, IL-8, IL-10, IL-17, IL-23, interferon IFN-g and tumor necrosis factor TNF-a) will be used using flow cytometry (FC) on schirmer filter papers.	8 weeks
Secondary	Efficacy of topical autologous PRP and PPP as measured by Ocular Surface Disease Index (OSDI) questionnaire	To evaluate the efficacy of topical autologous PRP and PPP four times a day in reducing symptoms of dry eye in ocular GVHD by Surface Disease Index (OSDI) questionnaire	8 weeks
Secondary	Efficacy of topical autologous PRP and PPP as measured by National Eye Institute-Visual Function Questionnaire (NEI-VFQ-25)	To evaluate the efficacy of topical autologous PRP and PPP four times a day in reducing symptoms of dry eye in ocular GVHD by National Eye Institute-Visual Function Questionnaire (NEI-VFQ-25)	8 weeks